Scholarlink

Background <p>New diagnoses of inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), can highlight health system burden and potentially give clues to disease aetiology. This population-based study aimed to measure the annual incidence of IBD over six years (2018–2023) in the Canterbury region of New Zealand.</p> Methods <p>The medical records from public and private gastroenterology clinics were examined for new patients with a confirmed diagnosis of IBD from 1 January 2018 to 31 December 2023. Demographic and disease information (including the Montreal phenotype) was gathered in a secure database. Information was collected prospectively from 2021 to 2023 and retrospectively from 2018 to 2020.</p> Results <p>The incidence of IBD in 2023 was 30.1 per 100,000 person-years (95% CI 25.9–34.7), CD: 14.8 (95% CI 11.9–18.1), and UC: 14.5 (95% CI 11.7–17.7). The average age was 35.0&#xa0;years (SD 17.2) and New Zealand European was the predominant ethnicity (83.4%), with smaller proportions of Māori (7.7%) and Pacific Islanders (1.7%).</p> <p>Between 2018 and&#xa0;2023, the annual incidence of IBD was 32.4 per 100,000 person-years. The proportion of CD diagnosed each year decreased, and in 2023, the proportion of CD was equivalent (49%) to the proportion with UC.</p> Conclusions <p>The incidence of IBD in Canterbury remains high, and the rates appeared stable over the six years 2018–2023, consistent with the stabilizing incidence stage of the 4-stage epidemiological model of IBD. Māori and Pacific Island ethnicities contributed a small number of cases of IBD, but the rates of IBD in these groups were higher than in previous studies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Incidence of Inflammatory Bowel Disease in Canterbury, New Zealand, 2018–2023

  • 期刊论文

  • 发表日期：

    2025年1月2日

查看全文
  • Angela J. Forbes,
  • Andrew S. Day,
  • Chris M. A. Frampton,
  • Richard B. Gearry

摘要

Background

New diagnoses of inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), can highlight health system burden and potentially give clues to disease aetiology. This population-based study aimed to measure the annual incidence of IBD over six years (2018–2023) in the Canterbury region of New Zealand.

Methods

The medical records from public and private gastroenterology clinics were examined for new patients with a confirmed diagnosis of IBD from 1 January 2018 to 31 December 2023. Demographic and disease information (including the Montreal phenotype) was gathered in a secure database. Information was collected prospectively from 2021 to 2023 and retrospectively from 2018 to 2020.

Results

The incidence of IBD in 2023 was 30.1 per 100,000 person-years (95% CI 25.9–34.7), CD: 14.8 (95% CI 11.9–18.1), and UC: 14.5 (95% CI 11.7–17.7). The average age was 35.0 years (SD 17.2) and New Zealand European was the predominant ethnicity (83.4%), with smaller proportions of Māori (7.7%) and Pacific Islanders (1.7%).

Between 2018 and 2023, the annual incidence of IBD was 32.4 per 100,000 person-years. The proportion of CD diagnosed each year decreased, and in 2023, the proportion of CD was equivalent (49%) to the proportion with UC.

Conclusions

The incidence of IBD in Canterbury remains high, and the rates appeared stable over the six years 2018–2023, consistent with the stabilizing incidence stage of the 4-stage epidemiological model of IBD. Māori and Pacific Island ethnicities contributed a small number of cases of IBD, but the rates of IBD in these groups were higher than in previous studies.